Kinfo
aTyr Pharma, Inc. logo

aTyr Pharma, Inc.

ATYRNASDAQHealthcare·US · USD
$7.56
-0.02 (-0.26%)
Prices as of November 10, 2026 · market closed

Price

Key statistics

Valuation
Market cap19.27M USD
Enterprise value-20.71M USD
Trailing P/E-9.08
Forward P/E-0.43
PEG ratio0.18
Price / sales101.43
Price / book0.55
Profitability
Gross margin0.00%
Operating margin-40856.32%
Profit margin0.00%
Return on assets-41.98%
Return on equity-93.68%
Income (TTM)
Revenue190.00K USD
Gross profit-60.22M USD
EBITDA-55.23M USD
Net income-53.32M USD
Diluted EPS-$21.64
Rev. growth (YoY)0.00%
Balance sheet
Total cash50.25M USD
Total debt10.92M USD
Debt / equity32.31
Current ratio3.15
Book value / share$13.76
Cash flow (TTM)
Operating cash flow-61.99M USD
Levered free cash flow-74.12M USD
Shares & price
Shares outstanding98.09M
Float2.45M
Held by institutions30.34%
Beta0.00
50-day MA$11.67
200-day MA$23.63
52-week high$7.98
52-week low$0.14
Dividends
Forward rate
$0.00
Yield
0.00%
Payout ratio
0.00%
Frequency
Unknown
Earnings (EPS)
DateEst.ActualSurprise2026-11-05-4.00-7.43−85.75%2026-08-07-5.00-4.40+12.00%2026-05-15-5.50-4.40+20.00%2026-05-040.780.87+11.54%2026-03-05-7.00-5.60+20.00%
About aTyr Pharma, Inc.

aTyr Pharma, Inc. is a clinical-stage biotechnology company focused on discovering and developing medicines based on tRNA synthetase biology. The company’s current work centers on efzofitimod, a selective NRP2 modulator being studied for interstitial lung diseases, including pulmonary sarcoidosis and systemic sclerosis-related ILD. aTyr Pharma also advances preclinical programs such as ATYR0101 for fibrosis and ATYR0750 for liver disorders, reflecting a pipeline aimed at inflammation, immune regulation, and tissue remodeling. Headquartered in San Diego, California, and founded in 2005, aTyr Pharma operates as a research-driven biopharmaceutical company with a focus on translating proprietary biology into potential therapeutic candidates for serious fibrotic and inflammatory conditions.

Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Sanjay S. Shukla M.D., M.S.
Employees
58
Headquarters
San Diego, CA, United States

Frequently asked questions about aTyr Pharma, Inc.